DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUC_I/AUC) RATIOS

10.1074/jbc.M300749200

2004, Drug Metab Rev, 6, 132

2003, Curr Drug Metab, 5, 393

2004, Pharmacopsychiatry, 37, 63, 10.1055/s-2004-815527

1994, Eur J Clin Pharmacol, 46, 3

10.1124/dmd.31.7.815

10.1046/j.1365-2125.2002.01669.x

1999, J Pharm Pharm Sci, 2, 47

2003, Rev Physiol Biochem Pharmacol, 146, 95, 10.1007/s10254-002-0003-8

1973, Biochemistry, 12, 2612, 10.1021/bi00738a010

1999, Drug Metab Dispos, 27, 1165

10.1124/mol.59.6.1464

10.1124/dmd.30.11.1257

2001, J Pharmacol Exp Ther, 299, 998

10.1124/dmd.31.9.1125

10.1016/j.bcp.2003.07.019

Dehal SS, Gagne PV, Crespi CL, and Patten CJ (2001) Characterization of a probe substrate and an inhibitor of UDP glucuronosyltransferase (UGT) 1A4 activity in human liver microsomes and cDNA expressed UGT enzymes. http://www.gentest.com. Poster at Annual Meeting of the American Association of Pharmaceutical Sciences.

1996, Int J Clin Pharmacol Ther, 34, 345

10.1016/S0920-1211(02)00007-4

2001, Acta Pol Pharm, 58, 345

1999, J Pharmacol Exp Ther, 291, 424

10.1016/S0165-6147(03)00049-X

10.1016/S0006-2952(03)00076-5

2003, Pharmacopsychiatry, 36, 134, 10.1055/s-2003-41198

1999, J Pharmacol Exp Ther, 289, 1169

Garnett WR (2002) Lamotrigine—interaction with other drugs, in Anti-epileptic Drugs, 5th ed (Levy RH, Mattson RH, Meldrum BS, and Perucca E eds) pp 300-331, Lippincott Williams & Wilkins, Philadelphia.

2003, Drug Metab Rev, 35, 46

Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, and Dijkstra HP (2004a) Bergamottin pharmacokinetics and contribution to the grapefruit juice-felodipine interaction in humans. Clin Pharmacol Ther, in press.

2004, Drug Metab Rev, 36, 299

10.1124/dmd.32.6.587

1998, Drug Metab Dispos, 27, 507

1987, Crit Care Med, 15, 751, 10.1097/00003246-198708000-00008

2002, J Huazhong Univ Sci Technol Med Sci, 22, 14, 10.1007/BF02904777

2001, Drug Metab Dispos, 29, 407

1995, Drug Metab Dispos, 23, 343

2003, Eur J Pharm Biopharm, 55, 339, 10.1016/S0939-6411(03)00022-5

10.1016/j.clpt.2003.12.004

1995, Int J Clin Pharmacol Ther, 33, 232

1976, J Pharm Sci, 65, 1253, 10.1002/jps.2600650832

1994, J Clin Pharmacol, 34, 754, 10.1002/j.1552-4604.1994.tb02036.x

1993, J Pharmacol Exp Ther, 264, 475

10.1124/dmd.30.6.694

1989, J Pharmacol Exp Ther, 249, 378

10.1124/jpet.102.038992

1994, Clin Pharmacol Ther, 56, 272, 10.1038/clpt.1994.137

10.2174/1389200023336992

1995, Drug Metab Dispos, 23, 631

10.1002/hup.403

10.1097/00004714-200110000-00008

10.1016/0163-7258(91)90065-T

1997, Cancer Res, 57, 284

2002, Toxicology, 181, 453

1995, Yakuri to Chiryo, 23, S1179

10.1001/jama.1990.03450210088038

2003, Biopharm Drug Dispos, 24, 245, 10.1002/bdd.361

10.1067/mcp.2001.115822

10.1124/dmd.32.2.235

1987, Dev Pharmacol Ther, 10, 413

10.1086/341209

10.1124/jpet.301.3.1042

1995, Rev Contemp Pharmacother, 6, 485

10.1016/0920-1211(91)90012-5

1996, J Pharmacol Exp Ther, 276, 658

10.1124/dmd.30.12.1364

10.1007/BF01059791

10.1345/aph.1C404

10.1016/0006-2952(91)90454-D

1997, J Clin Pharmacol, 37, 442, 10.1002/j.1552-4604.1997.tb04322.x

10.1124/dmd.31.1.98

1985, Clin Pharmacol Ther, 38, 121, 10.1038/clpt.1985.146

10.1124/dmd.31.6.762

10.1124/dmd.31.9.1086

Therapeutic Drugs (Editor - Sir Colin Dollery), Churchill Livingstone, New York, 1994 A, S1 48–49; B, 1 C334–335, C, 1 D96–97; D, 1 E100–101; E, 1 G13; F, S2 150; G, 2 M227; H, 2 O46; I S2 202; J S1, 212; K, 2 P13; L S2, 150; M 2, 149; N 2, 171; O, 2 227; P, S2 202; Q, S1, 212.

2000, Biopharm Drug Dispos, 21, 229, 10.1002/bdd.234

1998, Antimicrob Agents Chemother, 42, 1592, 10.1128/AAC.42.7.1592

10.1016/j.bcp.2003.08.025

10.1124/dmd.31.5.589

10.1124/dmd.30.11.1266

10.1124/dmd.30.8.883

10.2174/1389200033489235

2002, Drug Metab Dispos, 30, 1023

10.1023/A:1016215015530